Clinical Trials

Ex-OpenAI Researcher Miles Wang to Launch $2B AI Biotech Startup
Tech & Innovation Ex-OpenAI Researcher Miles Wang to Launch $2B AI Biotech Startup

The pharmaceutical landscape is currently witnessing a tectonic shift as Miles Wang, a former prominent researcher at OpenAI, prepares to launch a specialized drug discovery venture that bridges the gap between generative artificial intelligence and complex biotechnology. This development marks a

Trend Analysis: Precision Microbiome Cancer Therapy
Research & Development Trend Analysis: Precision Microbiome Cancer Therapy

The intricate and vastly complex machinery of the human immune system relies far more on the microscopic inhabitants of the digestive tract than on the expensive genetic modifications that frequently dominate contemporary pharmaceutical headlines. While the global medical community typically

Insilico and Bora Form $2.5 Billion AI Drug Alliance
Research & Development Insilico and Bora Form $2.5 Billion AI Drug Alliance

The fusion of generative artificial intelligence with traditional pharmaceutical manufacturing has reached a critical tipping point where computational blueprints now dictate the speed of global medical delivery. The current biopharmaceutical industry has moved beyond isolated computational

Liso-cel Shows Long-Term Efficacy in Aggressive Lymphoma
Research & Development Liso-cel Shows Long-Term Efficacy in Aggressive Lymphoma

The landscape of oncology has reached a pivotal juncture where terminal diagnoses for aggressive blood cancers are increasingly being redefined by the success of durable, long-term immunotherapy outcomes. Recent five-year clinical data for lisocabtagene maraleucel, commonly referred to as liso-cel,

3D Tumor Replicas Predict Drug Response in Lung Cancer
Research & Development 3D Tumor Replicas Predict Drug Response in Lung Cancer

For decades, the primary challenge in treating lung cancer has centered on the unpredictable way individual bodies react to standardized chemotherapy and targeted molecular therapies. Despite the advent of genomic sequencing, many patients still find themselves in a biological gray area where their

FDA Approves First Drug for Acquired Hypothalamic Obesity
Research & Development FDA Approves First Drug for Acquired Hypothalamic Obesity

The recent authorization by the Food and Drug Administration marks a transformative milestone for patients grappling with the relentless hunger and rapid weight gain associated with damage to the brain’s appetite-regulating center. For individuals suffering from acquired hypothalamic obesity, the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later